{"id":68068,"date":"2026-11-06T08:21:26","date_gmt":"2026-11-06T02:51:26","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=68068"},"modified":"2026-11-06T08:21:32","modified_gmt":"2026-11-06T02:51:32","slug":"interactive-cardiology-mcqs-29-cardiomyopathy","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/","title":{"rendered":"Interactive Cardiology MCQs 29: Cardiomyopathy"},"content":{"rendered":"\n<!-- Cardiology MCQs Part 29 (Full 25 Questions - Cardiomyopathy) - WordPress Safe Custom HTML Block -->\n<script src=\"https:\/\/cdn.tailwindcss.com?plugins=forms,typography,aspect-ratio\"><\/script>\n<script>\n  tailwind.config = {\n    corePlugins: { preflight: false }\n  }\n<\/script>\n\n<div id=\"mcq29-quiz-wrapper\" class=\"font-sans bg-slate-950 text-slate-100 p-4 md:p-8 rounded-3xl max-w-4xl mx-auto shadow-2xl relative overflow-hidden my-8 border border-solid border-cyan-500\/20\" style=\"box-sizing: border-box;\">\n  \n  <!-- Background Accents -->\n  <div class=\"absolute top-0 left-0 w-full h-full pointer-events-none opacity-10 bg-[radial-gradient(ellipse_at_center,_var(--tw-gradient-stops))] from-cyan-500 via-blue-900 to-slate-950\"><\/div>\n  \n  <!-- Header Banner -->\n  <div class=\"relative text-center pb-6 border-b border-solid border-cyan-500\/25 mb-8\">\n    <div class=\"inline-block bg-gradient-to-r from-cyan-500 via-blue-600 to-indigo-600 text-white font-black text-xs md:text-sm px-4 py-1.5 rounded-full uppercase tracking-wider shadow-lg mb-3 animate-pulse\">\n      \u26a1 Advanced Cardiology Series &#8211; Part 29\n    <\/div>\n    <h1 class=\"text-3xl md:text-5xl font-extrabold tracking-tight text-transparent bg-clip-text bg-gradient-to-r from-cyan-300 via-blue-400 to-indigo-400 m-0\">\n      Interactive Cardiology MCQs #29\n    <\/h1>\n    <p class=\"text-sm md:text-lg text-slate-300 mt-2 max-w-2xl mx-auto font-medium\">\n      Post-Graduate Level Masterclass: Cardiomyopathies\n    <\/p>\n  <\/div>\n\n  <!-- Real-Time Floating Scoreboard -->\n  <div class=\"sticky top-4 z-40 bg-slate-900\/90 backdrop-blur-md border-2 border-solid border-cyan-500\/40 rounded-2xl p-4 mb-8 shadow-xl flex flex-wrap items-center justify-between gap-4\">\n    <div class=\"flex items-center gap-3\">\n      <div class=\"text-3xl\">\ud83e\udec0<\/div>\n      <div>\n        <div class=\"text-[10px] uppercase font-extrabold tracking-widest text-cyan-300\">Live Scoreboard<\/div>\n        <div class=\"text-lg md:text-2xl font-black text-blue-300 flex items-center gap-1\">\n          <span id=\"mcq29-correct-count\">0<\/span><span class=\"text-slate-500 text-sm md:text-lg\">\/ 25 Correct<\/span>\n        <\/div>\n      <\/div>\n    <\/div>\n    <div class=\"flex items-center gap-2 bg-slate-950\/80 px-4 py-2 rounded-xl border border-solid border-slate-800\">\n      <span class=\"text-xs font-bold text-slate-400 uppercase tracking-wider\">Progress:<\/span>\n      <div class=\"w-24 md:w-36 bg-slate-800 h-3 rounded-full overflow-hidden\">\n        <div id=\"mcq29-progress-bar\" class=\"bg-gradient-to-r from-cyan-500 to-blue-500 h-full w-0 transition-all duration-300 rounded-full\"><\/div>\n      <\/div>\n      <span class=\"text-xs font-bold text-blue-300\"><span id=\"mcq29-answered-count\">0<\/span>\/25<\/span>\n    <\/div>\n  <\/div>\n\n  <!-- Quiz Questions Container -->\n  <div class=\"space-y-8 relative\">\n\n    <!-- Q1 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q1<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In patients with Hypertrophic Obstructive Cardiomyopathy (HOCM), dynamic left ventricular outflow tract (LVOT) obstruction is primarily driven by hypertrophy of the basal septum and which accompanying valvular phenomenon?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Mitral annular calcification can cause stenosis or regurgitation but is not the primary mechanism of dynamic LVOT obstruction in HOCM.\">A) Mitral annular calcification limiting leaflet excursion.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Dynamic LVOT obstruction in HOCM is classically caused by Systolic Anterior Motion (SAM) of the anterior mitral valve leaflet. The high-velocity blood flow through the narrowed LVOT creates a Venturi effect (drag forces), pulling the anterior mitral leaflet into the septum during systole, worsening the obstruction and causing eccentric mitral regurgitation. Reference: AHA\/ACC Guidelines for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy.\">B) Systolic Anterior Motion (SAM) of the anterior mitral valve leaflet.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Prolapse of the posterior leaflet into the left atrium causes mitral regurgitation, but it moves away from the LVOT, not into it.\">C) Prolapse of the posterior mitral leaflet into the left atrium.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Premature closure of the aortic valve can be a secondary echocardiographic finding due to sudden cessation of flow, but it is not the primary driver of the obstruction itself.\">D) Premature mid-systolic closure of the aortic valve.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q2 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q2<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Familial Hypertrophic Cardiomyopathy is most commonly inherited in an autosomal dominant pattern. Mutations in which two sarcomeric genes account for the vast majority of genotyped cases?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Mutations in the MYH7 (beta-myosin heavy chain) and MYBPC3 (myosin-binding protein C) genes are the most common causes of familial hypertrophic cardiomyopathy, accounting for up to 70 percent of cases where a genetic mutation is identified. These are genes encoding fundamental structural components of the cardiac sarcomere. Reference: Heart Failure Society of America (HFSA) Genetic Testing Guidelines.\">A) MYH7 and MYBPC3.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"PKP2 and DSP are desmosomal genes associated with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), not typically HCM.\">B) PKP2 and DSP.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"TTN (Titin) mutations are the most common genetic cause of Dilated Cardiomyopathy (DCM), not HCM.\">C) TTN and LMNA.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"SCN5A and KCNQ1 are ion channel mutations associated with Brugada syndrome and Long QT syndrome, respectively.\">D) SCN5A and KCNQ1.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q3 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q3<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          On an echocardiogram, a patient with heart failure with preserved ejection fraction (HFpEF) shows severe concentric left ventricular hypertrophy. Which specific global longitudinal strain (GLS) pattern is a highly sensitive and specific hallmark for Cardiac Amyloidosis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Isolated reduction in basal septal strain might be seen in localized ischemia or early hypertrophic cardiomyopathy, but it is not the classic 'cherry-on-top' pattern of amyloidosis.\">A) Isolated severe reduction in basal septal strain.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A uniform, global reduction in strain across all segments without a gradient is common in advanced dilated cardiomyopathy.\">B) Uniform, global reduction in strain across all left ventricular segments equally.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Cardiac amyloidosis classically presents with an 'apical sparing' pattern on 2D speckle-tracking echocardiography (global longitudinal strain). The basal and mid-ventricular segments show severely reduced (abnormal) strain, while the apical segments maintain relatively normal strain. On a polar map (bullseye plot), this creates the classic 'cherry-on-top' appearance. Reference: ASE Guidelines for Echocardiographic Assessment of the Left Heart.\">C) Severe reduction of strain in the basal and mid segments with relative preservation of apical strain (&#8216;apical sparing&#8217;).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Reduced apical strain with preserved basal strain is classically seen in Takotsubo (stress) cardiomyopathy (apical ballooning).\">D) Severe reduction of apical strain with normal basal strain.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q4 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q4<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A 28-year-old male from South America presents with heart failure, right bundle branch block, and a left anterior fascicular block. Echocardiography reveals a distinct apical aneurysm of the left ventricle with a relatively normal basal function. What is the most likely infectious etiology of his cardiomyopathy?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Toxoplasmosis can cause myocarditis, especially in immunocompromised patients, but it does not classically cause an isolated apical aneurysm.\">A) Toxoplasma gondii.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Chagas disease, caused by the protozoan Trypanosoma cruzi (endemic to Latin America), can lead to chronic Chagas Cardiomyopathy decades after the initial infection. The pathognomonic triad includes conduction system abnormalities (often RBBB with LAFB), severe ventricular arrhythmias, and localized left ventricular apical aneurysms (which often harbor thrombi) despite otherwise preserved basal function. Reference: AHA Scientific Statement on Chagas Cardiomyopathy.\">B) Trypanosoma cruzi.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Coxsackievirus B is a common cause of viral myocarditis leading to global dilated cardiomyopathy, not a specific, isolated apical aneurysm.\">C) Coxsackievirus B.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Borrelia burgdorferi causes Lyme carditis, which typically manifests as transient, reversible atrioventricular block, not a structural apical aneurysm.\">D) Borrelia burgdorferi.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q5 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q5<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), what is the classic diagnostic finding often seen on a 12-lead ECG in leads V1-V3?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Osborn waves (J waves) are positive deflections at the J point classically associated with severe hypothermia or hypercalcemia.\">A) Osborn (J) waves.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Delta waves indicate ventricular pre-excitation seen in Wolff-Parkinson-White (WPW) syndrome.\">B) Delta waves.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"An Epsilon wave is a classic, highly specific ECG sign for ARVC. It is defined as a small, reproducible notch or 'wiggle' located between the end of the QRS complex and the onset of the T wave (the ST segment), best seen in the right precordial leads (V1-V3). It represents delayed ventricular activation due to fibrofatty replacement of the right ventricular myocardium. Reference: International Task Force Criteria for ARVC.\">C) Epsilon waves.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Coved ST-segment elevation in V1-V3 is the hallmark of Brugada syndrome, not structurally-mediated ARVC.\">D) Coved ST-segment elevation.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q6 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q6<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Which of the following classes of pharmacological agents is strictly CONTRAINDICATED in patients with symptomatic Hypertrophic Obstructive Cardiomyopathy (HOCM) as it can acutely worsen the LVOT gradient?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Beta-blockers are the first-line therapy for HOCM. They decrease contractility and slow heart rate, allowing for better diastolic filling and reducing the LVOT gradient.\">A) Non-vasodilating beta-blockers (e.g., Metoprolol).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Pure vasodilators (like dihydropyridine calcium channel blockers, nitroglycerin, or high-dose ACE inhibitors) decrease afterload (systemic vascular resistance). In HOCM, decreasing afterload reduces the pressure keeping the LVOT open, causing the hyperdynamic ventricle to empty too quickly and exacerbating the systolic anterior motion (SAM) and LVOT obstruction. Preload reducers (like high-dose diuretics) are also relatively contraindicated as they decrease LV volume, tightening the LVOT. Reference: ACC\/AHA HOCM Guidelines.\">B) Pure peripheral vasodilators (e.g., Nifedipine, Nitrates).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Non-dihydropyridine calcium channel blockers (like verapamil) are acceptable second-line agents for HOCM because they possess negative inotropic properties which reduce the dynamic gradient.\">C) Non-dihydropyridine calcium channel blockers (e.g., Verapamil).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Disopyramide is a Class Ia antiarrhythmic that is actively used in HOCM for its strong negative inotropic effects to reduce the LVOT gradient.\">D) Disopyramide.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q7 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q7<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Mavacamten is a novel, first-in-class pharmacological agent approved for the treatment of symptomatic obstructive Hypertrophic Cardiomyopathy. What is its exact molecular mechanism of action?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Mavacamten is a first-in-class, oral, allosteric cardiac myosin ATPase inhibitor. In HCM, excessive myosin-actin cross-bridging leads to hypercontractility and impaired relaxation. Mavacamten reduces the number of myosin heads that can enter the 'on' state (cross-bridge formation), effectively decreasing contractility, relieving the LVOT obstruction, and improving myocardial energetics. Reference: EXPLORER-HCM trial.\">A) It acts as an allosteric inhibitor of cardiac myosin ATPase, reducing the formation of actin-myosin cross-bridges.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Phosphodiesterase-3 inhibition (e.g., milrinone) acts as a positive inotrope, which would dangerously worsen HOCM obstruction.\">B) It is a phosphodiesterase-3 inhibitor that increases intracellular cAMP, reducing myocardial stiffness.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Tafamidis acts as a Transthyretin (TTR) tetramer stabilizer for cardiac amyloidosis, not for HCM.\">C) It stabilizes transthyretin tetramers, preventing their dissociation and amyloid fibril formation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes the mechanism of I(f) channel blockers like ivabradine, which lower heart rate but do not address the core sarcomeric defect in HCM.\">D) It selectively blocks the I(f) current in the sinoatrial node to safely lower heart rate without vasodilation.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q8 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q8<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Cardiac MRI (CMR) is the gold standard for non-invasive tissue characterization in cardiomyopathies. In Cardiac Sarcoidosis, what is the most typical pattern of Late Gadolinium Enhancement (LGE)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Subendocardial LGE following a specific coronary territory is the classic hallmark of ischemic cardiomyopathy (prior myocardial infarction), not an infiltrative disease like sarcoidosis.\">A) Subendocardial enhancement following a distinct coronary arterial territory.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Diffuse, global subendocardial enhancement is the classic hallmark of Cardiac Amyloidosis, not sarcoidosis.\">B) Diffuse, global subendocardial enhancement with abnormal myocardial nulling.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Cardiac Sarcoidosis is a patchy, granulomatous disease. On CMR, it characteristically produces multifocal, patchy mid-wall or subepicardial Late Gadolinium Enhancement (LGE), most frequently involving the basal anteroseptal wall and the inferolateral wall. This basal septal involvement is why complete AV block is a very common clinical presentation. Reference: Heart Rhythm Society Expert Consensus Statement on Cardiac Sarcoidosis.\">C) Patchy, multifocal mid-wall or subepicardial enhancement, frequently involving the basal septum and lateral wall.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Thickened endocardial enhancement isolated to the apices is characteristic of Loeffler's endocarditis or Endomyocardial Fibrosis, not sarcoidosis.\">D) Dense endocardial enhancement restricted exclusively to the apices of both ventricles.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q9 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q9<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A 22-year-old male presents with severe, progressive hypertrophic cardiomyopathy. His ECG shows extreme voltage and a short PR interval with a delta wave (WPW pattern). He also has cognitive impairment. Genetic testing reveals a mutation in the LAMP2 gene. What is the diagnosis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Fabry disease is caused by an alpha-galactosidase A (GLA) deficiency and typically presents with concentric LVH later in life, neuropathic pain, and angiokeratomas.\">A) Fabry Disease.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Pompe disease (acid alpha-glucosidase deficiency) causes massive infantile hypertrophy but typically results in death within the first year of life without enzyme replacement, and is not defined by LAMP2.\">B) Pompe Disease.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Danon Disease is a rare, X-linked dominant lysosomal storage disorder caused by mutations in the LAMP2 gene. It is characterized by the classic clinical triad of extreme left ventricular hypertrophy (often progressing rapidly to heart failure), Wolff-Parkinson-White (WPW) pre-excitation on ECG, and mild skeletal myopathy with cognitive impairment. Reference: AHA Scientific Statement on Hypertrophic Cardiomyopathy.\">C) Danon Disease.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Friedreich Ataxia causes HCM and neurological issues, but is caused by a frataxin (FXN) gene trinucleotide repeat, not LAMP2.\">D) Friedreich Ataxia.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q10 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q10<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Differentiating Restrictive Cardiomyopathy (RCM) from Constrictive Pericarditis (CP) can be difficult. During invasive hemodynamic catheterization, how do the Left Ventricular (LV) and Right Ventricular (RV) systolic pressures respond to respiration in Constrictive Pericarditis versus Restrictive Cardiomyopathy?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Both conditions typically show equalization of end-diastolic pressures, making that resting metric unhelpful for differentiation; dynamic respiratory changes are required.\">A) In CP, they are perfectly equal at all times, whereas in RCM, the LV pressure is always massively higher than the RV pressure.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Because the rigid pericardium in CP isolates the heart from intrathoracic pressure changes and fixes total cardiac volume, increased venous return to the RV during inspiration forces the septum into the LV, dropping LV pressure while RV pressure rises. This produces 'Ventricular Discordance' (pressures move in opposite directions during respiration). In RCM, the stiff myocardium restricts both ventricles, but they are still exposed to intrathoracic pressure, causing 'Ventricular Concordance' (both LV and RV pressures rise and fall together with respiration). Reference: ACC\/AHA Guidelines for the Diagnosis of Pericardial Diseases.\">B) In CP, LV and RV pressures are discordant (move in opposite directions) during respiration. In RCM, they are concordant (move in the same direction).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the exact opposite of the true physiologic response. Discordance is the hallmark of CP due to enhanced ventricular interdependence.\">C) In CP, LV and RV pressures are concordant during respiration. In RCM, they are discordant.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Both conditions exhibit a prominent 'square root' sign (dip and plateau) in their diastolic pressure tracings; it does not reliably differentiate them.\">D) In CP, there is a lack of a &#8216;square root&#8217; sign on the diastolic tracing, whereas RCM demonstrates a profound square root sign.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q11 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q11<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient undergoing non-invasive diagnostic evaluation for suspected Cardiac Amyloidosis receives a Technetium-99m Pyrophosphate (Tc-99m PYP) scan. The scan shows &#8216;Grade 3&#8217; myocardial uptake (myocardial uptake is significantly greater than rib uptake). What does this specific finding strongly indicate?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While AL amyloidosis can involve the heart, it typically does not demonstrate strong, Grade 2 or 3 uptake on a PYP scan.\">A) It confirms Light Chain (AL) Cardiac Amyloidosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Technetium-99m Pyrophosphate (Tc-99m PYP) scintigraphy is highly specific for Transthyretin (TTR) Cardiac Amyloidosis (both wild-type and hereditary). When myocardial uptake is graded as 2 or 3 (equal to or greater than rib bone uptake), and blood tests rule out a monoclonal gammopathy, it provides a non-invasive, definitive diagnosis of ATTR amyloidosis, effectively bypassing the need for an endomyocardial biopsy. Reference: ASNC\/AHA Consensus on Cardiac Amyloidosis Imaging.\">B) It strongly confirms Transthyretin (ATTR) Cardiac Amyloidosis and can preclude the need for endomyocardial biopsy if serum\/urine light chains are negative.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Cardiac sarcoidosis is evaluated using FDG-PET, which looks for active inflammation, not a Tc-99m PYP bone tracer scan.\">C) It confirms active inflammatory Cardiac Sarcoidosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Negative or Grade 0 uptake rules out significant ATTR, but Grade 3 uptake is strongly positive.\">D) It is a completely negative scan, ruling out all forms of infiltrative cardiomyopathy.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q12 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q12<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient develops severe heart failure during the final month of pregnancy. Based on recent pathophysiological insights implicating oxidative stress and the cleavage of prolactin into an anti-angiogenic 16-kDa fragment, which specialized therapeutic agent is sometimes incorporated into the treatment of Peripartum Cardiomyopathy?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Current research suggests that in Peripartum Cardiomyopathy, oxidative stress causes the cleavage of the nursing hormone prolactin into a toxic, anti-angiogenic 16-kDa fragment that damages the cardiac endothelium and myocytes. Bromocriptine, a dopamine D2 receptor agonist, blocks the pituitary release of prolactin. In severe cases with severely reduced LVEF, adding bromocriptine (alongside standard heart failure therapy and anticoagulation) may significantly improve recovery. Reference: ESC Guidelines on the Management of Cardiovascular Diseases during Pregnancy.\">A) Bromocriptine.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Oxytocin stimulates uterine contraction and is not a treatment for peripartum cardiomyopathy; in fact, its cardiovascular side effects require careful monitoring.\">B) Oxytocin.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Estrogen therapy is contraindicated in the postpartum period due to a highly elevated risk of thromboembolism, and it does not treat the prolactin cleavage pathway.\">C) High-dose Estrogen.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Methotrexate is an immunosuppressant. While some CMPs (like sarcoidosis) respond to immunosuppression, Peripartum CMP is primarily neurohormonal\/vascular.\">D) Methotrexate.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q13 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q13<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Anthracycline-induced cardiotoxicity (e.g., from Doxorubicin chemotherapy) differs fundamentally from Trastuzumab-induced cardiotoxicity. Which statement accurately describes the clinical and cellular profile of Anthracycline toxicity?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Trastuzumab (Herceptin) toxicity (Type II), which usually causes temporary contractile dysfunction without cellular death.\">A) It is generally reversible, not dose-dependent, and is caused by functional myocardial stunning without ultrastructural changes.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Anthracycline cardiotoxicity (Type I) is classically dose-dependent (risk rises significantly with cumulative doses) and largely irreversible. At the cellular level, anthracyclines interfere with topoisomerase II beta, leading to oxidative stress, mitochondrial dysfunction, myocyte vacuolization, and permanent cell death (necrosis and apoptosis), resulting in a permanent dilated cardiomyopathy. Reference: ESC Guidelines on Cardio-Oncology.\">B) It is dose-dependent, largely irreversible, and characterized by direct cellular necrosis, myocyte vacuolization, and apoptosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Anthracyclines cause dilated cardiomyopathy, not a restrictive phenotype with eosinophilic infiltrates (which describes Loeffler Endocarditis).\">C) It exclusively causes a restrictive cardiomyopathy driven by massive eosinophilic infiltration of the endocardium.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While it can present late, the mechanism is not an autoimmune attack on the pericardium; it is direct cytotoxic injury to the myocardium.\">D) It presents as late-onset constrictive pericarditis driven by an autoimmune reaction to the drug.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q14 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q14<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Left Ventricular Non-Compaction (LVNC) is characterized by a &#8220;spongy&#8221; myocardium. Echocardiographic diagnosis (Jenni Criteria) relies on measuring the ratio of the non-compacted (trabeculated) layer to the compacted (solid) layer. What ratio, measured at end-systole, confirms the diagnosis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A ratio of 1.0 means the layers are equal; a much thicker non-compacted layer is required for diagnosis.\">A) A ratio greater than 1.0.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While 1.5 is abnormal, the established echocardiographic cutoff requires the trabeculated layer to be at least twice as thick.\">B) A ratio greater than 1.5.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"According to the Jenni echocardiographic criteria for LVNC, the diagnosis is made when there is a two-layered myocardium where the ratio of the non-compacted (trabeculated) endocardial layer to the compacted epicardial layer is strictly greater than 2.0 at end-systole, typically measured in the short-axis view at the apical or mid-ventricular level. Colour Doppler will also show blood flow deep within these intertrabecular recesses. Reference: ASE Guidelines for Left Ventricular Non-Compaction.\">C) A ratio greater than 2.0.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A ratio of 3.0 represents extreme non-compaction, but the diagnostic cutoff begins at 2.0.\">D) A ratio greater than 3.0.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q15 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q15<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In patients with Dilated Cardiomyopathy (DCM), guideline-directed medical therapy (GDMT) focuses on neurohormonal blockade. Which of the following is NOT a pillar of standard GDMT proven to reduce mortality in HFrEF?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Beta-blockers (like carvedilol or metoprolol succinate) are a fundamental pillar of HFrEF mortality reduction.\">A) Beta-blockers.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"SGLT2 inhibitors (like dapagliflozin) are now a class I indication and core pillar of GDMT for reducing mortality and hospitalizations in HFrEF.\">B) SGLT2 inhibitors.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"While loop diuretics (like furosemide) are essential for managing volume overload and relieving symptoms (congestion, edema) in Dilated Cardiomyopathy and heart failure, they have NEVER been proven in randomized clinical trials to reduce long-term mortality. The four pillars proven to reduce mortality are ARNI\/ACEi\/ARB, Beta-blockers, MRAs (spironolactone), and SGLT2 inhibitors. Reference: ACC\/AHA\/HFSA Heart Failure Guidelines.\">C) Loop Diuretics (e.g., Furosemide).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Mineralocorticoid Receptor Antagonists (like spironolactone) are a proven pillar for mortality reduction in HFrEF.\">D) Mineralocorticoid Receptor Antagonists (MRAs).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q16 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q16<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Hemochromatosis causes a toxic accumulation of iron in the myocardium. Which of the following statements regarding Hemochromatosis-induced cardiomyopathy is clinically accurate?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Endomyocardial biopsy is not required; Cardiac MRI T2* (T2 star) is the non-invasive gold standard for quantifying myocardial iron.\">A) Diagnosis strictly requires an endomyocardial biopsy, as imaging modalities cannot detect iron.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Iron overload cardiomyopathy initially presents with a Restrictive phenotype (diastolic dysfunction) due to stiff iron deposits, but progressively dilates into a Dilated phenotype (systolic failure) as myocytes die. Crucially, unlike amyloidosis or anthracycline toxicity, cardiac dysfunction from hemochromatosis is often entirely reversible if aggressive phlebotomy and iron chelation (e.g., deferoxamine) therapy are initiated early. Reference: Heart Failure Society of America Guidelines on Infiltrative Cardiomyopathies.\">B) It typically begins as a restrictive pattern, can progress to a dilated pattern, and is largely reversible with aggressive phlebotomy and chelation therapy.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Phlebotomy and chelation therapy are the primary, life-saving treatments; they are not contraindicated.\">C) Iron chelation therapy is strictly contraindicated as it accelerates myocardial necrosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Hemochromatosis causes structural remodeling leading to heart failure, not an isolated Long QT ion channel defect.\">D) It exclusively manifests as an electrical ion channelopathy (Long QT) without any structural remodeling.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q17 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q17<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient with a history of asthma and marked peripheral eosinophilia presents with restrictive cardiomyopathy and severe thickening of the endocardium in both apices, complicated by mural thrombi. What is the diagnosis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Carcinoid primarily affects the right-sided valves (tricuspid\/pulmonic) due to serotonin, not endocardial eosinophilic infiltration.\">A) Carcinoid Heart Disease.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Loeffler Endocarditis (a form of Hypereosinophilic Syndrome) is a rare restrictive cardiomyopathy. Persistent, massive eosinophilia results in toxic eosinophilic degranulation directly onto the endocardium. This causes intense endocardial inflammation, necrosis, and eventual dense fibrotic thickening with obliteration of the ventricular apices by fibrotic tissue and mural thrombi. Reference: World Health Organization Classification of Cardiomyopathies.\">B) Loeffler Endocarditis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Cardiac Sarcoidosis involves granulomas in the myocardium (often basal septum), not eosinophilic obliteration of the endocardial apices.\">C) Cardiac Sarcoidosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Endocardial Fibroelastosis is a pediatric condition causing a thick white endocardium, but is not driven by asthma\/eosinophilia.\">D) Endocardial Fibroelastosis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q18 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q18<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In patients diagnosed with Hypertrophic Cardiomyopathy (HCM), several major clinical risk factors are evaluated to determine the necessity of prophylactic Implantable Cardioverter-Defibrillator (ICD) placement. Which of the following is considered a major independent risk factor for Sudden Cardiac Death?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While resting gradients cause symptoms (dyspnea, angina), the pure magnitude of the gradient is not a primary independent predictor of sudden cardiac death.\">A) A resting LVOT gradient greater than 50 mmHg.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The decision to implant an ICD in HCM relies on evaluating major risk factors for sudden cardiac death (SCD). These include: a family history of SCD, unexplained recent syncope, Non-Sustained Ventricular Tachycardia (NSVT) on Holter, and massive left ventricular hypertrophy (defined as a maximal wall thickness greater than or equal to 30 mm). Any one of these can justify ICD placement. Reference: ACC\/AHA Guidelines for Hypertrophic Cardiomyopathy.\">B) Massive Left Ventricular wall thickness greater than or equal to 30 mm.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The presence of SAM is expected in obstructive HCM, but SAM itself is not one of the standardized independent risk factors for arrhythmic sudden death.\">C) The presence of Systolic Anterior Motion (SAM) on resting echocardiogram.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Diastolic dysfunction is ubiquitous in HCM and causes heart failure symptoms, but is not a primary trigger criterion for ICD implantation.\">D) Grade 3 diastolic dysfunction.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q19 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q19<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Duchenne Muscular Dystrophy (DMD) invariably involves the heart, eventually leading to a severe dilated cardiomyopathy. On cardiac MRI or autopsy, where does the myocardial fibrosis in DMD characteristically begin?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The anterior wall and apex are typically involved in ischemic disease (LAD territory), not early DMD.\">A) The anterior wall and apex.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The basal septum is the classic site for fibrosis in Cardiac Sarcoidosis.\">B) The basal anteroseptum.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In Duchenne Muscular Dystrophy (a lack of the dystrophin protein), mechanical stress during systole eventually causes myocyte death. For biomechanical reasons, this myocardial fibrosis and thinning classically begin in the posterobasal and inferolateral walls of the left ventricle before progressing to a global dilated cardiomyopathy. This produces a characteristic ECG finding: deep, narrow Q waves in the lateral leads and tall R waves in V1\/V2. Reference: AHA Scientific Statement on Cardiomyopathies in Muscular Dystrophies.\">C) The posterobasal and inferolateral walls.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Right ventricular free wall fibrosis is the hallmark of ARVC, not DMD.\">D) The right ventricular free wall.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q20 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q20<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Takotsubo Cardiomyopathy (Stress-Induced Cardiomyopathy) mimics an acute myocardial infarction but involves transient regional wall motion abnormalities. Which pathophysiological mechanism is most widely accepted as the primary trigger?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Plaque rupture defines a classic acute myocardial infarction (Type 1 MI), whereas Takotsubo is defined by the absence of culprit plaque rupture.\">A) Acute atherosclerotic plaque rupture in the mid-LAD.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Takotsubo Cardiomyopathy is typically triggered by severe emotional or physical stress. The widely accepted mechanism is a sudden, massive surge of circulating catecholamines (epinephrine\/norepinephrine). The apical myocardium contains a higher density of beta-adrenergic receptors than the base. At massive concentrations, epinephrine shifts from stimulatory to inhibitory (negative inotropy) at the beta-2 receptors, causing toxic stunning and the classic 'apical ballooning' appearance. Reference: ESC Guidelines on Acute Coronary Syndromes (MINOCA section).\">B) A massive surge of circulating catecholamines causing toxic microvascular dysfunction and apical myocardial stunning.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Autoimmune destruction characterizes conditions like giant cell myocarditis, not the rapidly reversible Takotsubo.\">C) An acute autoimmune destruction of the apical sarcomeres following viral illness.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While coronary spasm (Prinzmetal) can occur, it is a localized epicardial phenomenon. Takotsubo involves global apical microvascular stunning beyond a single epicardial territory.\">D) Sustained spasm of the epicardial circumflex artery.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q21 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q21<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In patients with advanced Dilated Cardiomyopathy and Left Bundle Branch Block (LBBB), Cardiac Resynchronization Therapy (CRT) is indicated. What is the primary hemodynamic goal achieved by biventricular pacing in this population?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Pacing primarily corrects electrical timing; it does not shrink the physical dimensions of the mitral valve annulus (though reverse remodeling over months may help secondarily).\">A) Immediate mechanical reduction of the mitral valve annulus size.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In DCM with LBBB, the right ventricle contracts before the lateral wall of the left ventricle. This dyssynchrony causes the septum to bulge abnormally, wasting energy and worsening mitral regurgitation. CRT (biventricular pacing) restores simultaneous contraction of the septum and lateral free wall. This eliminates the wasted mechanical work, drastically improves left ventricular pump efficiency (increasing forward stroke volume), and facilitates long-term reverse remodeling. Reference: HRS\/ACC\/AHA Guidelines for Device-Based Therapy.\">B) Restoring mechanical synchrony between the septum and the lateral wall to improve pump efficiency.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While some CRTs have ICD capabilities, the biventricular pacing aspect aims to restore synchrony, not to over-pace the sinus node.\">C) Overdriving the sinus node to maintain a constant heart rate above 80 bpm.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Pacing cannot dissolve fibrotic scar tissue; it only coordinates the remaining viable myocardium.\">D) Dissolving myocardial fibrotic scar tissue through high-voltage electrical stimulation.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q22 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q22<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Alcoholic Cardiomyopathy represents a toxic form of dilated cardiomyopathy. If a patient with severe alcoholic cardiomyopathy strictly and permanently abstains from all alcohol consumption, what is the typical expected clinical trajectory?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Unlike anthracycline toxicity, toxic damage from alcohol is often largely reversible, not permanent and relentlessly progressive.\">A) The disease is permanent and will relentlessly progress to end-stage heart failure regardless of abstinence.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Alcoholic cardiomyopathy is directly driven by the toxic effects of ethanol and its metabolites (like acetaldehyde) on myocardial protein synthesis and calcium homeostasis. A defining and unique characteristic of alcoholic cardiomyopathy is that complete, strict abstinence from alcohol (coupled with standard heart failure medications) frequently leads to significant and sometimes complete recovery of left ventricular ejection fraction and reversal of the dilatation over months to years. Reference: ACC\/AHA Heart Failure Guidelines on Toxic Cardiomyopathies.\">B) Significant and potentially complete recovery of left ventricular ejection fraction and reversal of dilatation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The remodeling is macroscopic (myocardial recovery); it does not convert a dilated heart into a hypertrophic one.\">C) Rapid transition from a dilated phenotype into a massive restrictive hypertrophic phenotype.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Pericardial calcification is seen in constrictive pericarditis (e.g., from tuberculosis or radiation), not from alcohol cessation.\">D) Development of severe pericardial calcification as the myocardium heals.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q23 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q23<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Which specialized echocardiographic modality is essential for accurately identifying and measuring the dynamic LVOT gradient in Hypertrophic Obstructive Cardiomyopathy, especially when provoked by a Valsalva maneuver?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"M-mode is a 1D measurement tool excellent for timing structures (like SAM), but it cannot measure blood flow velocities or pressure gradients.\">A) M-Mode echocardiography.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Pulsed-Wave Doppler is used for low velocities (like mitral inflow). High LVOT velocities in HOCM will cause aliasing (wrap-around error) on PW Doppler.\">B) Pulsed-Wave (PW) Doppler.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In HOCM, the dynamic obstruction causes very high-velocity blood flow through the LVOT (often greater than 3-4 m\/s). To measure these high velocities accurately without 'aliasing' (the signal wrapping around the screen), Continuous-Wave (CW) Doppler must be used. The peak velocity measured by CW Doppler is then converted to a pressure gradient using the simplified Bernoulli equation (Delta P = 4v^2). A classic 'dagger-shaped' late-peaking CW envelope is seen. Reference: ASE Guidelines for Echocardiographic Assessment of HOCM.\">C) Continuous-Wave (CW) Doppler.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Tissue Doppler measures the slow velocity of the actual heart muscle contracting, not the high-velocity blood flow through the outflow tract.\">D) Tissue Doppler Imaging (TDI).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q24 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q24<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Endocardial Fibroelastosis (EFE) is a rare, severe cause of restrictive cardiomyopathy seen almost exclusively in which specific patient demographic?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Amyloidosis is the classic restrictive cardiomyopathy of the elderly. EFE is fundamentally a pediatric disease.\">A) Elderly males over the age of 70.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Pregnant women are at risk for peripartum dilated cardiomyopathy, not endocardial fibroelastosis.\">B) Post-partum females in their third trimester.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Endocardial Fibroelastosis (EFE) is a rare disease found almost exclusively in infants and children (often within the first two years of life). It is characterized by a diffuse, severe thickening of the ventricular endocardium by fibrous and elastic tissue, leading to a pearly-white endocardium and severe restrictive physiology. It can be primary or secondary to congenital heart defects like Hypoplastic Left Heart Syndrome or aortic stenosis. Reference: Pediatric Cardiology Guidelines on Cardiomyopathies.\">C) Infants and young children, often within the first two years of life.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Athletes can develop physiological 'athlete's heart' (hypertrophy), but do not develop endocardial fibroelastosis.\">D) Elite endurance athletes.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q25 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q25<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), the pathophysiological hallmark is the progressive replacement of right ventricular myocardium with fibrofatty tissue. This disease is fundamentally caused by genetic mutations affecting which critical cellular structure?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The sarcomere (actin\/myosin) is mutated in Hypertrophic Cardiomyopathy, not ARVC.\">A) The Sarcomere.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"ARVC is fundamentally a disease of the Desmosome. Desmosomes are critical intercellular junction complexes that mechanically bind adjacent cardiac myocytes together. Mutations in desmosomal proteins (most commonly Plakophilin-2 or PKP2, Desmoplakin, and Desmoglein-2) cause these junctions to break down under mechanical stress. The dying myocytes are then replaced by fibrofatty scar tissue, which serves as a substrate for dangerous re-entrant ventricular tachycardias. Reference: Heart Rhythm Society Consensus on ARVC.\">B) The Desmosome.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Lysosomes are affected in storage diseases like Danon, Fabry, and Pompe disease, not ARVC.\">C) The Lysosome.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Ion channels are mutated in pure electrical diseases (channelopathies) like Long QT and Brugada syndrome. ARVC has a profound structural (fibrofatty) component.\">D) Voltage-gated sodium ion channels.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n  <\/div>\n<\/div>\n\n<script>\n  let mcq29Correct = 0;\n  let mcq29Answered = 0;\n  const mcq29Total = 25;\n\n  document.querySelectorAll('#mcq29-quiz-wrapper .quiz-card').forEach(card => {\n    const buttons = card.querySelectorAll('.opt-btn');\n    buttons.forEach(btn => {\n      btn.addEventListener('click', function() {\n        if (card.getAttribute('data-answered') === 'true') return;\n        card.setAttribute('data-answered', 'true');\n        mcq29Answered++;\n\n        document.getElementById('mcq29-answered-count').innerText = mcq29Answered;\n        const pct = (mcq29Answered \/ mcq29Total) * 100;\n        document.getElementById('mcq29-progress-bar').style.width = pct + '%';\n\n        buttons.forEach(b => {\n          b.disabled = true;\n          b.classList.remove('hover:bg-slate-900', 'cursor-pointer');\n          b.classList.add('opacity-50', 'cursor-not-allowed');\n        });\n\n        const isCorrect = this.getAttribute('data-correct') === 'true';\n        const explanation = this.getAttribute('data-explanation');\n\n        if (isCorrect) {\n          mcq29Correct++;\n          document.getElementById('mcq29-correct-count').innerText = mcq29Correct;\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-teal-950\/80', 'border-teal-500', 'text-teal-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10004; CORRECT!<\/span>';\n        } else {\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-cyan-950\/80', 'border-blue-500', 'text-cyan-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10006; INCORRECT<\/span>';\n\n          buttons.forEach(b => {\n            if (b.getAttribute('data-correct') === 'true') {\n              b.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n              b.classList.add('bg-teal-950\/40', 'border-teal-500\/55', 'text-teal-200', 'opacity-100', 'border-2');\n              b.innerHTML += ' <span class=\"font-bold\">&#10004; (Correct)<\/span>';\n            }\n          });\n        }\n\n        const feedback = card.querySelector('.feedback-box');\n        feedback.innerHTML = `\n          <div class=\"font-extrabold uppercase tracking-widest text-xs mb-2 ${isCorrect ? 'text-teal-400' : 'text-cyan-400'}\">\n            ${isCorrect ? 'Clinical Explanation & Reference' : 'Explanation, Correct Answer & Reference'}\n          <\/div>\n          <p class=\"m-0\">${explanation}<\/p>\n        `;\n        feedback.classList.remove('hidden');\n        feedback.classList.add('block', isCorrect ? 'bg-teal-950\/45' : 'bg-cyan-950\/20', 'border-2', 'border-solid', isCorrect ? 'border-teal-500\/30' : 'border-blue-500\/30', 'text-slate-200', 'mt-4');\n      });\n    });\n  });\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>\u26a1 Advanced Cardiology Series &#8211; Part 29 Interactive Cardiology MCQs #29 Post-Graduate Level Masterclass: Cardiomyopathies \ud83e\udec0 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 In patients with Hypertrophic Obstructive Cardiomyopathy (HOCM), dynamic left ventricular outflow tract (LVOT) obstruction is primarily driven by hypertrophy of the basal septum and which accompanying valvular phenomenon? A) Mitral annular [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":68069,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","nfd_image_url":"","nfd_onboarding_generated":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-68068","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Interactive Cardiology MCQs 29: Cardiomyopathy - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interactive Cardiology MCQs 29: Cardiomyopathy - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"\u26a1 Advanced Cardiology Series &#8211; Part 29 Interactive Cardiology MCQs #29 Post-Graduate Level Masterclass: Cardiomyopathies \ud83e\udec0 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 In patients with Hypertrophic Obstructive Cardiomyopathy (HOCM), dynamic left ventricular outflow tract (LVOT) obstruction is primarily driven by hypertrophy of the basal septum and which accompanying valvular phenomenon? A) Mitral annular [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T02:51:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-06T02:51:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1208\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Interactive Cardiology MCQs 29: Cardiomyopathy\",\"datePublished\":\"2026-11-06T02:51:26+00:00\",\"dateModified\":\"2026-11-06T02:51:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/\"},\"wordCount\":1683,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/\",\"name\":\"Interactive Cardiology MCQs 29: Cardiomyopathy - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg\",\"datePublished\":\"2026-11-06T02:51:26+00:00\",\"dateModified\":\"2026-11-06T02:51:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg\",\"width\":1208,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-29-cardiomyopathy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interactive Cardiology MCQs 29: Cardiomyopathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interactive Cardiology MCQs 29: Cardiomyopathy - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/","og_locale":"en_US","og_type":"article","og_title":"Interactive Cardiology MCQs 29: Cardiomyopathy - All About Cardiovascular System and Disorders","og_description":"\u26a1 Advanced Cardiology Series &#8211; Part 29 Interactive Cardiology MCQs #29 Post-Graduate Level Masterclass: Cardiomyopathies \ud83e\udec0 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 In patients with Hypertrophic Obstructive Cardiomyopathy (HOCM), dynamic left ventricular outflow tract (LVOT) obstruction is primarily driven by hypertrophy of the basal septum and which accompanying valvular phenomenon? A) Mitral annular [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-11-06T02:51:26+00:00","article_modified_time":"2026-11-06T02:51:32+00:00","og_image":[{"width":1208,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Interactive Cardiology MCQs 29: Cardiomyopathy","datePublished":"2026-11-06T02:51:26+00:00","dateModified":"2026-11-06T02:51:32+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/"},"wordCount":1683,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/","url":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/","name":"Interactive Cardiology MCQs 29: Cardiomyopathy - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg","datePublished":"2026-11-06T02:51:26+00:00","dateModified":"2026-11-06T02:51:32+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-29-Cardiomyopathy.jpg","width":1208,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-29-cardiomyopathy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Interactive Cardiology MCQs 29: Cardiomyopathy"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=68068"}],"version-history":[{"count":1,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68068\/revisions"}],"predecessor-version":[{"id":68070,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68068\/revisions\/68070"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/68069"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=68068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=68068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=68068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}